Recombinant Proteins: The Engineered Revolution | Community Health

Recombinant proteins, produced through genetic engineering, have revolutionized the field of biotechnology. Since the first recombinant protein, human insulin, was approved by the FDA in 1982, the industry has grown exponentially, with companies like Genentech and Amgen leading the charge. The use of recombinant proteins has improved the treatment of various diseases, including diabetes, cancer, and autoimmune disorders. However, concerns surrounding the high cost of these therapies and potential long-term side effects have sparked controversy. With advancements in gene editing technologies like CRISPR, the production of recombinant proteins is becoming more efficient and cost-effective. As of 2022, the global market for recombinant proteins was valued at over $100 billion, with an expected growth rate of 10% per annum. The future of recombinant proteins holds immense promise, with potential applications in regenerative medicine and gene therapy.